Homepage
Author:
Celularity Inc.
Posted Date:
June 4, 2026
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
Celularity Inc.
June 4, 2026
Celularity Releases CEO Letter to Shareholders
Celularity Inc.
June 3, 2026
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Celularity Inc.
June 3, 2026
Celularity Receives Nasdaq Notice Regarding Form 10-Q
Celularity Inc.
May 29, 2026
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
Celularity Inc.
May 1, 2026
Celularity Announces Closing of Transaction with NexGel
Celularity Inc.
April 21, 2026
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
Celularity Inc.
April 17, 2026
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
Celularity Inc.
March 12, 2026
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
Celularity Inc.
March 10, 2026
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
Celularity Inc.
February 10, 2026
